Telix Pharmaceuticals Ltd (OTCPK:TLPPF)
$ 10.45 0 (0%) Market Cap: 3.41 Bil Enterprise Value: 3.34 Bil PE Ratio: 950.00 PB Ratio: 33.71 GF Score: 78/100

Telix Pharmaceuticals Ltd Innovation in Urology to Feature Key Opinion Leaders in Prostate and Kidney Cancer Transcript

Jun 21, 2023 / 12:30PM GMT
Release Date Price: $8.4 (+11.26%)
Kyahn Williamson
Telix Pharmaceuticals Limited - SVP of Corporate Communications & IR

Okay. All right. Good morning, ladies and gentlemen. My name is Kyahn Williamson, and I'm the SVP of Investor Relations and Corporate Communications at Telix. I'd really like to thank you all for taking the time to join our session today, both to the people attending here in person and via the webcast. Today's session has been designed to give our shareholders a deeper look into Telix's urology pipeline and understand how we are building on the Illuccix, prostate cancer imaging agent to build a truly unique end-to-end offering for our urology and urologic oncology customer base.

Being here in New York is a great opportunity to bring together some of our U.S.-based senior leaders, our external clinical experts, and provide this unique opportunity for our shareholders here in North America and around the globe to hear about our pipeline and some recent company news. Can I ask you just to take a note of our standard disclaimer? And now to move to the agenda. As you'll see, we have a really great lineup of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot